Use of global gene expression patterns in mechanistic studies of oestrogen action in MCF7 human breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 114, Issue 1-2, 2009, Pages 21-32

  Sadler, A J ^a   Pugazhendhi, D ^a   Darbre, P D ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Antioestrogen; Antioestrogen resistance; Breast cancer; Environmental oestrogens; Fulvestrant; Global gene expression; Long term oestrogen deprivation; Microarray; Oestrogen; Parabens

Indexed keywords

ANTIESTROGEN; ESTROGEN; FULVESTRANT;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; ESTROGEN ACTIVITY; GENE CONTROL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; UNINDEXED SEQUENCE; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 62949103545     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.12.017     Document Type: Article

References (81)

1. Lipworth L. Epidemiology of breast cancer. Eur. J. Cancer Prevent. 4 (1995) 7-30
2. Key T.J., Verkasalo P.K., and Banks E. Epidemiology of breast cancer. Lancet Oncol. 2 (2001) 133-140
3. Miller W.R. Estrogen and Breast Cancer (1996), Chapman and Hall
4. In: Lonning P.E. (Ed). Endocrinology and treatment of breast cancer. Clin. Endocrinol. Metab. 18 (2004) 1-130
5. Soule H.D., Vazquez A., Long A., Albert S., and Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst. 51 (1973) 1409-1413
6. Osborne C.K., Hobbs K., and Trent J.M. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res. Treat. 9 (1987) 111-121
7. Lippman M.E., and Dickson R.B. Regulatory Mechanisms in Breast Cancer (1990), Kluwer Academic
8. In: Pasqualini J. (Ed). Breast Cancer Prognosis, Treatment and Prevention (2008), Informa Healthcare Publishing
9. Nicholson R.I., Staka C., Boyns F., Hutcheson I.R., and Gee J.M.W. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr. Relat. Cancer 11 (2004) 623-641
10. Martin L.A., Farmer I., Johnston S.R.D., Ali S., and Dowsett M. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr. Relat. Cancer 12 (2005) S75-S84
11. Sabnis G.J., Jelovac D., Long B., and Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res. 65 (2005) 3903-3910
12. Staka C.M., Nicholson R.I., and Gee J.M.W. Acquired resistance to oestrogen deprivation: role for growth factor signaling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocr. Relat. Cancer 12 (2005) S85-S97
13. Gee J.M.W., Shaw V.E., Hiscoz S.E., McClelland R.A., Rushmere N.K., and Nicholson R.I. Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr. Relat. Cancer 13 (2006) S77-S88
14. Yue W., Fan P., Wang J., Li Y., and Santen R.J. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J. Steroid Biochem. Mol. Biol. 106 (2007) 102-110
15. Santen R.J., Song R.X., Masamura S., Yue W., Fan P., Sogon T., Hayashi S., Nakachi K., and Eguchi H. Adaptation to estradiol deprivation causes upregulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv. Exp. Med. 630 (2008) 19-34
16. Song R.X.D., Mor G., Naftolin F., McPherson R.A., Song J., Zhang Z., Yue W., Wang J.P., and Santen R.J. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol. J. Natl. Cancer Inst. 93 (2001) 1714-1723
17. Lewis J.S., Meeke K., Osipo C., Ross E.A., Kidawi N., Li T., Bell E., Chandel N.S., and Jordan V.C. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J. Natl. Cancer Inst. 97 (2005) 1746-1759
18. In: Phimister B. (Ed). The chipping forecast. Nat. Genet. 21 (1999) 1-60
19. Charpentier A.H., Bednarek A.K., Daniel R.L., Hawkins K.A., Laflin K.J., Gaddis S., MacLeod M.C., and Aldaz C.M. Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res. 60 (2000) 5977-5983
20. Soulez M., and Parker M.G. Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling. J. Mol. Endocrinol. 27 (2001) 259-274
21. Inoue A., Yoshida N., Omoto Y., Oguchi S., Yamori T., Kiyama R., and Hayashi S. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J. Mol. Endocrinol. 29 (2002) 175-192
22. Kroll T., Odyvanova L., Clement J.H., Platzer C., Naumann A., Marr N., Hoffken K., and Wolfl S. Molecular characterization of breast cancer cell lines by expression profiling. J. Cancer Res. Clin. Oncol. 128 (2002) 125-134
23. Lobenhofer E.K., Bennett L., Cable P.L., Li L., Bushel P.R., and Afshari C.A. Regulation of DNA replication fork genes by 17β-oestradiol. Mol. Endocrinol. 16 (2002) 1215-1229
24. Cunliffe H.E., Ringner M., Bilke S., Walker R.L., Cheung J.M., Chen Y., and Meltzer P.S. The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles. Cancer Res. 63 (2003) 7158-7166
25. Frasor J., Danes J.M., Komm B., Chang K.C.N., Lyttle C.R., and Katzenellenbogen B.S. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 (2003) 4562-4574
26. Hayashi S.I., Eguchi H., Tanimoto K., Yoshida T., Omoto Y., Inoue A., Yosida N., and Yamaguchi Y. The expression and function of estrogen receptor α and β in human breast cancer and its clinical application. Endocr. Relat. Cancer 10 (2003) 193-202
27. Cicatiello L., Scaoglio C., Altucci L., Cancemi M., Natoli G., Facchiano A., Iazzetti G., Calgero R., Biglia N., Bortoli M.D., Sfiligio C., Sismondi P., Bresciani F., and Weisz A. A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transciptome. J. Mol. Endocrinol. 32 (2004) 719-775
28. Tee M.K., Rogatsky I., Foster C.T., Cvoro A., An J., Christy R.J., Yamamoto K.R., and Leitman D.C. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol. Biol. Cell 15 (2004) 1262-1272
29. Wang D.Y., Fulthorpe R., Liss S.N., and Edwards E.A. Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol. Endocrinol. 18 (2004) 402-411
30. DeNardo D.G., Kim H.T., Hilsenbeck S., Ciba V., Tsimelzon A., and Brown P.H. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol. Endocrinol. 19 (2005) 362-378
31. Gadal F., Starzec A., Bozic C., Brochet C.P., Malinge S., Ozanne V., Vicenzi J., Buffat L., Perret G., Iris F., and Crepin M. Integrative analysis of gene expression patterns predicts specific modulations of defined cell functions by estrogen and tamoxifen in MCF7 breast cancer cells. J. Mol. Endocrinol. 34 (2005) 61-75
32. Santen R.J., Lobenhofer E.K., Afshari C.A., Bao Y., and Song R.X. Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. Breast Cancer Res. Treat. 94 (2005) 213-223
33. Pugazhendhi D., Sadler A.J., and Darbre P.D. Comparison of the global gene expression profiles produced by methylparaben, n-butylparaben and 17β-oestradiol in MCF7 human breast cancer cells. J. Appl. Toxicol. 27 (2007) 67-77
34. Katzenellenbogen B.S., Kendra K.L., Norman M.J., and Berthois Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res. 47 (1987) 4355-4360
35. Welshons W.V., and Jordan V.C. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur. J. Cancer Clin. Oncol. 23 (1987) 1935-1939
36. Jeng M.H., Shupnik M.A., Bender T.P., Westin E.H., Bandyopadhyay D., Kumar R., Masamura S., and Santen R.J. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139 (1998) 4164-4174
37. Stephen R., and Darbre P.D. Loss of growth inhibitory effects of retinoic acid in human breast cancer cells following long-term exposure to retinoic acid. Br. J. Cancer 83 (2000) 1183-1191
38. Stephen R.L., Shaw L.E., Larsen C., Corcoran D., and Darbre P.D. Insulin-like growth factor receptor levels are regulated by cell density and by long-term estrogen deprivation in MCF7 human breast cancer cells. J. Biol. Chem. 276 (2001) 40080-40086
39. Chan C.M.W., Martin L.A., Johnston S.R.D., Ali S., and Dowsett M. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J. Steroid Biochem. Mol. Biol. 81 (2002) 333-341
40. Yue W., Wang J.P., Conaway M.R., Li Y., and Santen R.J. Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J. Steroid Biochem. Mol. Biol. 86 (2003) 265-274
41. Shaw L.E., Sadler A.J., Pugazhendhi D., and Darbre P.D. Changes in oestrogen receptor-α and -β during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex ICI 182,780) in MCF7 human breast cancer cells. J. Steroid Biochem. Mol. Biol. 99 (2006) 19-32
42. Mullick A., and Chambon P. Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D. Cancer Res. 50 (1990) 333-338
43. Knowlden J.M., Hutcheson I.R., Jones H.E., Madden T., Gee J.M., Harper M.E., Barrow D., Wakeling A.E., and Nicholson R.I. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 (2003) 1032-1044
44. Brunner N., Frandsen T.L., Holst-Hansen C., Bei M., Thompson E.W., Wakeling A.E., Lippman M.E., and Clarke R. MCF7/LCC2: a 4-Hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI182,7. Cancer Res. 53 (1993) 3229-3232
45. Badia E., Duchesne M.J., Semlali A., Fuentes M., Giamarchi C., Richard-Foy H., Nicholas J.C., and Pons M. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res. 60 (2000) 4130-4138
46. Lykkesfeldt A.E., Larsen S.S., and Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int. J. Cancer 61 (1995) 529-534
47. McClelland R.A., Barrow D., Madden T.A., Dutkowski C.M., Pamment J., Knowlden J.M., Gee J.M.W., and Nicholson R.I. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI182,780 (Faslodex). Endocrinology 142 (2001) 2776-2788
48. Sommer A., Hoffman J., Lichtner R.B., Schneider M.R., and Parczyk K. Studies on the development of resistance to the pure antiestrogen Faslodex™ in three human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 85 (2003) 33-47
49. Darbre P.D. Environmental oestrogens, cosmetics and breast cancer. Best Pract. Res. Clin. Endocrinol. Metab. 20 (2006) 121-143
50. Soto A.M., Maffini M.V., Schaeberle C.M., and Sonnenschein C. Strengths and weaknesses of in vitro assays for estrogenic and androgenic activity. Best Pract. Res. Clin. Endocrinol. Metab. 20 (2006) 15-33
51. Darbre P.D., and Harvey P.W. Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks. J. Appl. Toxicol. 28 (2008) 561-578
52. Darbre P.D., and Daly R.J. Effects of oestrogen on human breast cancer cells in culture. Proc. R. Soc. Edinburgh 95B (1989) 119-132
53. Berthois Y., Katzenellenbogen J.A., and Katzenellenbogen B.S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 2496-2500
54. Darbre P., Yates J., Curtis S.A., and King R.J.B. Effect of estradiol on human breast cancer cells in culture. Cancer Res. 43 (1983) 349-354
55. Daly R.J., and Darbre P.D. Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Res. 50 (1990) 5868-5875
56. Pugazhendhi D., Watson K.A., Mills S., Botting N., Pope G.S., and Darbre P.D. Effect of sulphation on the oestrogen agonist activity of the phytoestrogens genistein and daidzein in MCF7 human breast cancer cells. J. Endocrinol. 197 (2008) 503-515
57. Murphy C.S., Meisner L.F., Wu S.Q., and Jordan V.C. Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. Eur. J. Cancer Clin. Oncol. 25 (1989) 1777-1788
58. Reddel R.R., Sutherland I.E., Shine J., and Sutherland R.L. Genetic instability and the development of steroid hormone insensitivity in cultured T47D human breast cancer cells. Cancer Res. 48 (1988) 4340-4347
59. Saceda M., Lippman M.E., Chambon P., Lindsey R.L., Ponglikitimongkol M., Puente M., and Martin M.B. Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol. Endocrinol. 2 (1988) 1157-1162
60. Masamura S., Santner S.J., Heitjan D.F., and Santen R.J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab. 80 (1995) 2918-2925
61. Shim W.S., Conaway M., Masamura S., Yue W., Wang J.P., Kumar R., and Santen R.J. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141 (2000) 396-405
62. Yue W., Wang J.P., Conaway M., Masamura S., Li Y., and Santen R.J. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 143 (2002) 3221-3229
63. A.J. Sadler, Identification of novel genes associated with endocrine resistance in breast cancer, Ph.D. Thesis, University of Reading, UK, 2006.
64. Zudaire E., Martinez A., and Cuttita F. Adrenomedullin and cancer. Regul. Pept. 112 (2003) 175-183
65. Nagaya N., Mori H., Murakami S., Kangawa K., and Kitamura S. Adrenomedullin: angiogenesis and gene therapy. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288 (2005) R1432-R1437
66. Ribatti D., Nico B., Spinazzi R., Vacca A., and Nussdorfer G.G. The role of adrenomedullin in angiogenesis. Peptides 26 (2005) 1670-1675
67. Nikitenko L.L., Fox S.B., Kehoe S., Rees M.C.P., and Bicknell R. Adrenomedullin and tumour angiogenesis. Br. J. Cancer 94 (2006) 1-7
68. Masiakowski P., Breathnach R., Bloch J., Gannon F., Krust A., and Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 10 (1982) 7895-7903
69. Brunner N., Boulay V., Fojo A., Freter C.E., Lippman M.E., and Clarke R. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res. 53 (1993) 283-290
70. Du K., Herzig S., Kulkarni R.N., and Montminy M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300 (2003) 1574-1577
71. Dauvois S., Danielian P.S., White R., and Parker M.G. Antiestrogen ICI164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4037-4041
72. Giamarchi C., Chailleux C., Callige M., Rochaix P., Trouche D., and Richard-Foy H. Two antiestrogens affect differently chromatin remodeling of trefoil factor 1 (pS2) gene and the fate of estrogen receptor in MCF7 cells. Biochim. Biophys. Acta 1578 (2002) 12-20
73. Fan M., Bigsby R.M., and Nephew K.P. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor(ER)-α and essential for the antiproliferative activity of ICI 182,780 in ERα-positive breast cancer cells. Mol. Endocrinol. 17 (2003) 356-365
74. H.F. Woods (Chairman), Phytoestrogens and Health, Crown copyright, 2002.
75. Darbre P.D. Oestrogens in the environment. Educ. Chem. 39 (2002) 124-128
76. Elder R.L. Final report on the safety assessment of methylparaben, ethylparaben, propylparaben and butylparaben. J. Am. College Toxicol. 3 (1984) 147-209
77. Soni M.G., Carabin I.G., and Burdock G.A. Safety assessment of esters of p-hydroxybenzoic acid (parabens). Food Chem. Toxicol. 43 (2005) 985-1015
78. Moggs J.G., Ashby J., Tinwell H., Lim F.L., Moore D.J., Kimber I., and Orphanides G. The need to decide if all estrogens are intrinsically similar. Environ. Health Perspect. 112 (2004) 1137-1142
79. Singleton D.W., Feng Y., Yang J., Puga A., Lee A.V., and Khan S.A. Gene expression profiling reveals novel regulation by bisphenol-A in estrogen receptor-α-positive human cells. Environ. Res. 100 (2006) 86-92
80. Terasaka S., Inoue A., Tanji M., and Kiyama R. Expression profiling of estrogen-responsive genes in breast cancer cells treated with alkylphenols, chlorinated phenols, parabens, or bis- and benzoylphenols for evaluation of estrogenic activity. Toxicol. Lett. 163 (2006) 130-141
81. Dip R., Lenz S., Antignac J.P., LeBizec B., Gmiender H., and Naegli H. Global gene expression profiles induced by phytoestrogens in human breast cancer cells. Endocr. Relat. Cancer 15 (2008) 161-173